ImmunoGen Inc. [NASDAQ: IMGN] gained 5.40% on the last trading session, reaching $4.10 price per share at the time. The company report on April 13, 2023 that ImmunoGen Announces Conference Call to Discuss Its First Quarter 2023 Operating Results.
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 28, 2023 to discuss its first quarter 2023 operating results. Management will also provide a brief update on the business.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
ImmunoGen Inc. represents 254.41 million in outstanding shares, while the company has a total market value of $887.98 million with the latest information. IMGN stock price has been found in the range of $3.91 to $4.165.
If compared to the average trading volume of 3.21M shares, IMGN reached a trading volume of 2214959 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about ImmunoGen Inc. [IMGN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IMGN shares is $12.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IMGN stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Truist have made an estimate for ImmunoGen Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 21, 2022. While these analysts kept the previous recommendation, Barclays raised their target price to Overweight. The new note on the price target was released on September 09, 2022, representing the official price target for ImmunoGen Inc. stock. Previously, the target price had yet another drop from $9 to $6, while RBC Capital Mkts kept a Sector Perform rating on IMGN stock.
The Average True Range (ATR) for ImmunoGen Inc. is set at 0.20, with the Price to Sales ratio for IMGN stock in the period of the last 12 months amounting to 8.16. The Price to Book ratio for the last quarter was 6.72, with the Price to Cash per share for the same quarter was set at 1.27.
Trading performance analysis for IMGN stock
ImmunoGen Inc. [IMGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.40. With this latest performance, IMGN shares dropped by -1.20% in over the last four-week period, additionally sinking by -29.07% over the last 6 months – not to mention a drop of -22.20% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IMGN stock in for the last two-week period is set at 55.12, with the RSI for the last a single of trading hit 60.40, and the three-weeks RSI is set at 51.81 for ImmunoGen Inc. [IMGN]. The present Moving Average for the last 50 days of trading for this stock 4.08, while it was recorded at 3.96 for the last single week of trading, and 4.94 for the last 200 days.
ImmunoGen Inc. [IMGN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and ImmunoGen Inc. [IMGN] shares currently have an operating margin of -203.06 and a Gross Margin at +98.20. ImmunoGen Inc.’s Net Margin is presently recorded at -204.93.
Return on Total Capital for IMGN is now -75.06, given the latest momentum, and Return on Invested Capital for the company is -78.74. Return on Equity for this stock declined to -92.61, with Return on Assets sitting at -50.97. When it comes to the capital structure of this company, ImmunoGen Inc. [IMGN] has a Total Debt to Total Equity ratio set at 30.39. Additionally, IMGN Total Debt to Total Capital is recorded at 23.31, with Total Debt to Total Assets ending up at 13.57. Long-Term Debt to Equity for the company is recorded at 22.20, with the Long-Term Debt to Total Capital now at 17.03.
Reflecting on the efficiency of the workforce at the company, ImmunoGen Inc. [IMGN] managed to generate an average of -$804,798 per employee. Receivables Turnover for the company is 6.82 with a Total Asset Turnover recorded at a value of 0.25.ImmunoGen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.50 and a Current Ratio set at 2.50.
An analysis of insider ownership at ImmunoGen Inc. [IMGN]
There are presently around $793 million, or 93.10% of IMGN stock, in the hands of institutional investors. The top three institutional holders of IMGN stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 21,853,958, which is approximately 0.517% of the company’s market cap and around 0.30% of the total institutional ownership; BLACKROCK INC., holding 18,016,002 shares of the stock with an approximate value of $70.08 million in IMGN stocks shares; and STATE STREET CORP, currently with $68.11 million in IMGN stock with ownership of nearly 19.961% of the company’s market capitalization.
Positions in ImmunoGen Inc. stocks held by institutional investors increased at the end of Friday and at the time of the Friday reporting period, where 92 institutional holders increased their position in ImmunoGen Inc. [NASDAQ:IMGN] by around 33,650,354 shares. Additionally, 115 investors decreased positions by around 28,586,374 shares, while 37 investors held positions by with 141,602,481 shares. The mentioned changes placed institutional holdings at 203,839,209 shares, according to the latest SEC report filing. IMGN stock had 24 new institutional investments in for a total of 9,424,841 shares, while 47 institutional investors sold positions of 11,592,030 shares during the same period.